Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.62 |
| ▸ | PRCP | P42785 | 3/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.54 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23947756 | 0.75 | HDAC8 (0.60) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL23948084 | 0.75 | HDAC8 (0.60) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL25047674 | 0.74 | HDAC8 (0.58) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL24419737 | 0.74 | HDAC8 (0.58) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL16705702 | 0.74 | PRCP (1.00) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL6369541 | 0.74 | PRCP (1.00) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL25050848 | 0.74 | HDAC8 (0.65) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| Iodide SCHEMBL27518894 | 0.73 | PRCP (0.97) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL1016391 | 0.73 | HDAC8 (0.60) | HDAC8PRCPHDAC1HDAC2HDAC3 | |
| SCHEMBL12046719 | 0.72 | HHAT (0.64) | HDAC8PRCPHHATCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | HDAC8 988/4885PRCP 1119/4885HDAC1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.